Rossari Biotech Limited — Others, 19-07-2025: ESOP/ESOS/ESPS

Rossari Biotech's Board of Directors has approved the unaudited financial results for the quarter ended June 30, 2025. Consolidated profit after tax was Rs 33.60 crore, while standalone profit after tax was Rs 26.23 crore. Additionally, the company allotted 375 equity shares, each with a face value of Rs 2, under the ESOP 2019 at an exercise price of Rs 425 per share. This allotment increases the company's total issued and paid-up equity share capital to Rs 11.07 crore, comprising 55,366,966 equity shares. These approvals highlight the company's financial standing and capital structure changes.